Early triple antiviral therapy for COVID-19

alwin shared this article with you from Inoreader [Correspondence] Early triple antiviral therapy for COVID-19 Via The Lancet In the trial led by Ivan Hung and colleagues,1 adults admitted to hospital with COVID-19 received two antiviral treatment combinations. In the combination group, 52 (60%) of 86 patients received interferon beta-1b (most patients received one to two doses), lopinavir–ritonavir, and ribavirin, based on the time elapsed from symptom onset to the start of study treatment (median 5 days [IQR 4–7]). However, 34 (40%) patients had interferon beta-1b omitted due to concerns of proinflammatory side-effects in patients who started treatment 7 days or more after symptom onset. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.